Video

Dr. Hanna on Challenges With Consolidation Immunotherapy in Lung Cancer

Nasser H. Hanna, MD, discusses challenges in consolation immunotherapy for patients with lung cancer.

Nasser H. Hanna, MD, professor of medicine, Indiana University, discusses challenges in consolation immunotherapy for patients with lung cancer.

The biggest challenge is when patients are given consolidation immunotherapy is typically at the same time patients would naturally get radiation pneumonitis, explains Hanna. Symptoms can include inflammation of the lungs, cough, fever, and shortness of breath. Physicians must decide whether the symptoms are related to radiation or immunotherapy because the management is different, says Hanna.

Immune-related pneumonitis can be very complicated and usually requires a pulmonary and infectious disease consult as well as prolonged steroids, according to Hanna. Atypical infections can occur—including viral, fungal, and bacterial infections—and some patients get bronchiolitis obliterans with organizing pneumonia. A question Hanna has for this patient population is whether patients who have low-grade pneumonitis can be rechallenged with consolidation immunotherapy.

<<< View more from the 2019 New York Lung Cancers Symposium

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO